Health Care and Life Sciences M&A Discussion and Networking Day

McDermott Will & Emery, and various international law firms, was pleased to host an exclusive health and life sciences M&A symposium on June 13, following the ABA International Section Life Sciences conference in Copenhagen.

Leading experts from the industry and various international lawyers discussed the latest developments in health and life sciences transactions, with a particular focus on how investors can manage potential regulatory barriers. Key topics included:

• Cross-border drug trading: Regulatory challenges within the EU and beyond
  Regulatory restrictions: Do the regulatory restrictions, such as the corporate practice of medicine doctrine, keep health service markets national and hinder the emergence of global players?
• eHealth platform mergers and acquisitions: The big data value proposition of eHealth platforms to “traditional players” in the health sciences space
• Big pharma and venture capital investments: Research and development through acquisition
• Generics: Regulatory constraints to their growth and the emergence of global players
• Panellists included the management of a leading mail-order pharmacy, representatives from big and small pharma companies, international health service providers for countries in Europe, public payers, the European Commission, and private equity investors.